fallback.jpg
 

DRUG DISCOVERY PARTNERSHIP

 

Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine

KEY FACTS:

  • Sema4 is a publicly traded, AI-driven genomic and clinical data intelligence platform company. BioSymetrics is a phenomics-driven drug discovery company.

  • Together, the companies will apply a multi-omics approach, including phenomics and genomics, to drug discovery.

  • The companies will initiate up to 10 therapeutic programs in areas of high unmet need where multi-omics offers a differentiated approach to discovering drugs.

  • Initial therapeutic focus is in cardiovascular, rare and neurological diseases.

    Learn more by reading the press release below

VIDEO: Strategic Partners + Innovators

The partners will leverage Sema4’s proprietary health intelligence platform, Centrellis, and BioSymetrics’ phenotypic drug discovery platform, Elion, to discover new treatments.

Hear more about this partnership from Sema4 Founder and CEO Eric Schadt, PhD, and BioSymetrics Co-Founder and CEO Anthony Iacovone.

  • “Connecting the dots between human clinical and genomic data, and experimental model systems, using advanced machine learning, increases the probability of successfully advancing new drugs that work well for more patients.”

    — Anthony Iacovone, Co-Founder and CEO, BioSymetrics

  • “We’re excited to work with BioSymetrics to discover higher value, de-risked drug candidates for patients. The power of applying our predictive network modeling to drug discovery will result in greater success, lower attrition, and a deeper understanding of the patient journey as it relates to identifying more personalized treatments.”

    — Eric Schadt, PhD, Founder and CEO, Sema4

  • “With Sema4, we are taking a multi-omic view of cardiovascular, neurological and rare disease and building a unique link between what we see in the clinic and what we observe in the lab, with great potential for improved treatment paths for patients.”

    — Gabriel Musso, PhD,Co-Founder and Chief Scientific Officer, BioSymetrics

  • “The scientific, operational and overall team synergies between Sema4 and BioSymetrics, under the umbrella of a common goal to advance precision medicine, create a great deal of excitement about this partnership and our ability to create tangible results.”

    — Matt Fusco, Chief Operating Officer, BioSymetrics

  • “AI-powered drug discovery is the hottest sector in biotech. With Sema4, we offer a unique competitive advantage that layers a multi-omic approach with advanced machine learning and experimental modeling for superior biological translation into drugs.”

    — Stacie Calad-Thomson, PhD, Chief Strategy Officer and Head of Drug Discovery, BioSymetrics